The 7th World Conference on Targeting Phage Therapy 2024 is set to take place on June 20-21 at the Corinthia Palace Malta, introducing the latest advancements within the field of phage research and therapy.
Credit: Phage Therapy 2024
The 7th World Conference on Targeting Phage Therapy 2024 is set to take place on June 20-21 at the Corinthia Palace Malta, introducing the latest advancements within the field of phage research and therapy.
Robert T. Schooley, M.D., Professor of Medicine at the University of California, San Diego, and Co-Director of the Center for Innovative Phage Applications and Therapeutics, will lead the discourse, presenting insights and strategies essential to Phage Therapy in his talk titled “Phage Therapeutics 2024: Essential Translational Research Components for Clinical Trials.”
Agenda at a Glance
Day One: will focus on Phages, Hosts & Microbiome, exploring current research on phageome, microbiome-phageome interactions, and the role of phages in various dysbiosis conditions. It will also shed light on emerging trends and innovative approaches in phage therapy, covering topics such as combating phage resistance, synthetic phages, and designing clinical studies.
Day Two: will feature sessions on the transition of phage research to clinical applications and a review of ethical and regulatory considerations in phage therapy.
Targeting Phage Therapy 2024 Speakers Line-Up
• Robert T. Schooley, University of California, San Diego, USA
Phage Therapeutics 2024: The Critical Role of Translational Research in Clinical Trials
• Jean-Paul Pirnay, Queen Astrid Military Hospital, Belgium
Magistral Phage Preparations: Is This the Model for Everyone?
• Barbara Brenner, Kanzlei BRENNER, Germany
Regulatory restrictions vs. Human Rights, the Hippocratic oath and the Freedom of therapy– The legal aspect of phage therapy
• Nannan Wu, Shanghai Public Health Clinical Center, Fudan University, China
Phage Therapy: A Glimpse into Clinical Studies Involving Over 150 Cases
• Graham F. Hatfull, University of Pittsburgh, USA
Mycobacteriophages and Their Therapeutic Potential
• Paul Turner, Yale University, USA
Selection for Phage Resistance Reduces Virulence of Shigella flexneri
• Pieter-Jan Ceyssens, Sciensano, Belgium
Quality control of phage Active Pharmaceutical Ingredients (APIs) in Belgium
• Wolfgang Weninger, Medical University of Vienna, Austria
The Phageome in Normal and Inflamed Human Skin
• Sabrina Green, KU Leuven, Belgium
Making Antibiotics Great Again: Phage resistance in vivo correlates to resensitivity to antibiotics in pan-resistant Pseudomonas aeruginosa
• Rodrigo Ibarra Chávez, University of Copenhagen, Denmark
Phage Satellites, a Diversity of Extradimensional Symbionts and Pathways to Phage Therapy
• Domenico Frezza, University of Roma Tor Vergata, Italy
Towards efficient phage therapies: investigation of phage / bacteria equilibrium with metagenome of dark matter in natural samples
• Eugene V Koonin, National Institutes of Health, USA
Evolution and megataxonomy of viruses: the place of phages in the virosphere
• Federica Briani, University of Milan, Italy
Addressing Phage Resistance to Enhance the Robustness of Phage Therapy for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
• Jumpei Fujiki, University of California San Diego, USA
Phage therapy: Targeting intestinal bacterial microbiota for the treatment of Liver disease
Call For Abstract & Recognition of Excellence
Abstract submission for short oral and poster presentations is open. You can share your latest phage research and findings in front of an international audience during Targeting Phage Therapy 2024 in Malta.
Awards will be assigned to the best scientific contribution, best oral presentation, and best poster presentation. Abstract Submission Details.
Keeping Up with Phage Therapy 2024: Where to Find the Latest Updates
LinkedIn | Newsletter Archive/Subscription| 2024 Website
